Oral cancer management involves surgery, radiotherapy, chemotherapy, or combined chemoradiotherapy. Although these modalities improve survival, they frequently produce oral toxicities that impair function, comfort and treatment compliance. Oral mucositis is the most common and debilitating complication, often accompanied by xerostomia, dysgeusia, dysphagia, hyposalivation, trismus and opportunistic infections. Severe mucositis causes intense pain, nutritional compromise, increased healthcare costs and may necessitate treatment interruptions. Current management is largely symptomatic and fails to prevent tissue injury. Photo biomodulation (PBM) therapy is a non-pharmacological supportive treatment using low intensity red or near infrared lasers. It stimulates mitochondrial activity and adenosine triphosphate production, thus reduces inflammation, enhances wound healing and provides analgesia. Randomized trials and meta-analyses demonstrate significant reductions in mucositis incidence, severity, duration and associated pain. MASCC/ISOO guidelines recommend PBM when applied with appropriate parameters. This review summarizes mechanisms, clinical evidence and guideline-based use, highlighting PBM as an effective safe and patient centred strategy for optimizing supportive care in oral cancer. Standardization of protocols, multidisciplinary approach, and future research like large scale randomized controlled trials (RCTs) are essential for effective and globally applicable healthcare delivery. Such integrated strategy is likely to improve not only patient’s quality of life but also supports oncologic treatment for diverse populations.